This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine levels or intrinsic anti-tumour activity in participants with advanced metastatic colorectal cancer, ovarian cancer, renal cancer or pancreatic cancer.
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Original English text from ClinicalTrials.gov
✓ Qualifies
Simplified criteria — AI translation
VA Loma Linda Healthcare System
Loma Linda, United States
Sutter Cancer Center Sacramento
Sacramento, United States
Sibley Memorial Hospital - a member of Johns Hopkins medicine
Washington D.C., United States
21st Century Oncology
Fort Myers, United States
Miami Cancer Center
Miami, United States
Sarasota Memorial Health Care System
Sarasota, United States
Moffitt Cancer Center
Tampa, United States
ASCLEPES Research Centers
Weeki Wachee, United States
University of Iowa Hospitals and Clinics - Holden Comprehensive Cancer Center
Iowa City, United States
Medstar Franklin Square
Baltimore, United States
University of Nebraska Medical Center
Omaha, United States
Dartmouth-Hitchcock Medical Center
Lebanon, United States
MD Anderson Cancer Center at Cooper Hospital
Camden, United States
Feinstein Institutes for Medical Research - Northwell Health
Manhasset, United States
Columbia University Medical Center
New York, United States
Montefiore Hospital
The Bronx, United States
Levine Cancer Institute - Atrium Health
Charlotte, United States
East Carolina University
Greenville, United States
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, United States
Oklahoma University - Stephenson Cancer Center
Oklahoma City, United States
Oregon Health & Science University
Portland, United States
University of Pittsburgh Medical Center
Pittsburgh, United States
Medical University of South Carolina - Hollings Cancer Center
Charleston, United States
Prisma Health (formerly Greenville Health System)
Greenville, United States
University of Texas Southwestern Medical Center
Dallas, United States
West Virginia University Medicine
Morgantown, United States
AZ Sint-Lucas
Bruges, Belgium
UZ Antwerp
Edegem, Belgium
AZ Maria Middelares
Ghent, Belgium
Jolimont Hospital
La Louvière, Belgium
AZ Delta
Roeselare, Belgium
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/25/2026.
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.
We use Google Analytics to understand how you use our tools and to improve them. We don't collect health data and we don't show ads. You can decline - the site will work exactly the same. Privacy policy